Efficacy evaluation of DOTAREM®-enhanced MRA compared to GADOVIST®–enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases

GUERBET0 个研究点目标入组 188 人开始时间: 2009年7月7日最近更新: 2012年4月24日

适应症

试验速览

暂无简介。

•Male or female, aged = 18 years
•Patient with infrarenal aorta or chronic lower limb ischemia with various clinical signs of gravity (stages II-IV according to the classification of Leriche and Fontaine) or/and Doppler ultrasonography indicating abdominal or lower limb arteriopathy.
•Patient scheduled for a conventional X-Ray angiography (intra-arterial Digital Substraction Angiography = DSA) within 30 days of MRA with a minimum time interval of at least 24 hours between the 2 examinations.
•Female of childbearing potential must have effective contraception (contraceptive pill or Intra-Uterine Device), or be surgically sterilized, or post-menopausal (minimum 12 months of amenorrhea) or must have a documented negative urine or blood pregnancy test at screening
•Patient able to understand and who have provided written informed consent to participate in the trial.
•Patient with national health insurance
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patient with a contraindication to MRI (e.g., pacemaker, aneurysm clip, severe claustrophobia, metallic joint replacement or others according to the imaging laboratory's standard practice).
•Patient with known severe adverse drug reaction or contraindication to one of the investigational products (Dotarem® or Gadovist®).
•Patient having received any contrast media within 48 hours prior to administration of investigational product for the enhanced-MRA.
•Patient planned to undergo therapeutic intervention in abdominal or lower limb vessels between the time of MRA and X-ray Angiography will be performed.
•Patient who had a major cardiovascular event within 30 days prior to the inclusion.
•Patient treated with unilateral hip replacement, abdominal aortic or iliac graft or stent.
•Patient having participated in any investigational drug study within 30 days prior the study enrolment.
•Any condition which, based on the investigator's clinical judgement, would prevent the patient from completing all trial assessments and visits (for example: mental or physical incapacity, language comprehension, geographical localisation, etc…).
•Patient under guardianship and/or Inability or unwillingness to cooperate with the requirements of this trial.
•Pregnant or breast-feeding patient.
•Patients already included in this trial

发起方